1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNevada State Opioid Response Grant (SOR 4) is sponsored by Nevada Bureau of Behavioral Health, Wellness and Prevention (BBHWP). Nevada's SOR grant funds projects to combat opioid and stimulant epidemics, supporting community stakeholders.
Get alerted about grants like this
Get emailed when new opportunities from “Nevada Bureau of Behavioral Health, Wellness and Prevention (BBHWP)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Nevada State Opioid Response Grant (SOR 4) Nevada State Opioid Response Grant (SOR 4) Request for Applications Announcement: Nevada State Opioid Response Grant (SOR 4) The Bureau of Behavioral Health, Wellness and Prevention (BBHWP) is pleased to announce the availability of funding through the SOR 4 grant.
This funding opportunity is in response to the urgent need to address the opioid and stimulant crisis plaguing Nevada’s communities. Utilizing the latest SOR award, BBHWP received applications from community stakeholders for projects to support the state’s efforts to combat the opioid and stimulant epidemics and save lives. The project period will run from January 1, 2025 through September 29, 2027.
For all recipients of both the SOR 3 and the SOR 4 grants, please see the attached list of SOR 3 NCE & SOR 4 Projects If you have questions about your funding status, please reach out to the SOR Program
According to the current listing, eligibility includes: Community stakeholders in Nevada. Confirm the full requirements in the official notice before applying.
Nevada State Opioid Response Grant (SOR 4) is funded by Nevada Bureau of Behavioral Health, Wellness and Prevention (BBHWP). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Nevada. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
SAMHSA's June 11 release of eight FY26 grant programs ranges from $600K to $9.2M and lands under the Trump-Kennedy-Burgum Great American Recovery Initiative. The SBIRT NOFO's 30-application cap means the deadline is functionally first-come, first-served.
Read articleARPA-H selected 13 research teams for EVIDENT, a $139.4M initiative to develop objective clinical endpoints for rapid-acting behavioral health therapies including psilocybin. At least $50M will match state psychedelic research investments under a Trump executive order.
Read articleARPA-H's $139.4M EVIDENT initiative selects 13 research teams to build objective biomarkers for psilocybin, neuromodulation, and rapid-acting mental health therapies.
Read article